A dual-channel intestinal-liver-heart-lung organ-on-a-chip system and its fabrication method

By designing a dual-channel intestinal-liver-heart-lung organ-on-a-chip system and using a pneumatic microvalve system to achieve dynamic switching of multiple culture modes, this technology solves the problem of difficulty in simulating the transorganizational transport of microplastics and differences in cardiotoxicity in existing technologies, and provides an efficient environmental health risk assessment tool.

CN123107828APending Publication Date: 2026-11-17QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611446360.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-17
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing organ-on-a-chip technology has difficulty simultaneously simulating the transorganizational transport of microplastics via both respiratory and digestive pathways and the differences in cardiotoxicity. Traditional models suffer from problems such as long experimental cycles, high costs, and incomparable results.

Method used

A dual-channel intestinal-liver-heart-lung organ-on-a-chip system was designed, employing a three-layer chip body that integrates multiple cell culture chambers and circulation pathways. A pneumatic microvalve system enables dynamic switching of multiple culture modes, simulating the cross-barrier transport process of microplastics via different pathways.

Benefits of technology

It enables direct comparison of cardiotoxicity caused by different exposure routes under unified experimental conditions, and provides a health risk assessment platform for environmental pollutants that is closer to the real state in vivo, which is significantly better than traditional models in terms of stability and reliability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107828A_ABST
    Figure CN123107828A_ABST
Patent Text Reader

Abstract

This invention proposes a dual-channel gut-liver-heart-lung organ-on-a-chip system and its fabrication method, belonging to the field of microfluidic organ-on-a-chip. The system includes: a chip body, comprising, from bottom to top, a microvalve layer, a flexible film layer, and a microchannel layer; the microchannel layer integrates multiple cell culture chambers and circulation pathways; the circulation pathways include a first circulation pathway and a second circulation pathway; the flexible film layer is disposed between the microchannel layer and the microvalve layer, used to isolate the fluid channels from the pneumatic control layer, and serves as a deformable structure during the microvalve actuation process; the microvalve layer contains multiple independent pneumatic microvalve chambers, and by adjusting the air pressure within the chambers to change the deformation of the flexible film, the reversible opening and closing of the microchannels is controlled, achieving dynamic switching between multiple culture modes. This invention enables direct comparison of the cardiotoxicity of microplastics under different exposure pathways, providing an in vitro research platform that closely approximates the in vivo real-world conditions for assessing the systemic health risks of environmental pollutants.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of microfluidic organ-on-a-chip technology, and particularly relates to a dual-channel intestinal-liver-heart-lung organ-on-a-chip system and its preparation method. Background Technology

[0002] The statements in this section are merely background information related to the present invention and do not necessarily constitute prior art.

[0003] Microplastics, referring to plastic particles with a diameter of less than 5 mm, have not only become a new type of environmental pollutant but can also enter the human body and cause harm to human health. Currently, it is believed that the main routes of microplastic entry into the human body include inhalation and dietary intake. After entering the body, they can be transported across the epithelial barrier and accumulate in distal organs. The heart, as a typical high-perfusion, high-metabolic organ, may become one of the important target organs for microplastic toxicity after long-term exposure to exogenous particles in the circulatory system. However, there are significant differences in the transport pathways of microplastics entering the body via the respiratory and digestive routes. Respiratory exposure can bypass the first-pass effect of the liver and directly enter the systemic circulation, while digestive exposure requires absorption by the intestines and metabolism by the liver before entering the circulatory system. Whether these two routes lead to different cardiotoxic effects and the mechanisms underlying them remain unclear.

[0004] Traditional toxicity assessment methods primarily rely on two-dimensional cell culture models and animal models. Two-dimensional cell cultures are structurally simple and cannot simulate the complex interactions between organs in vivo; while animal models can reflect systemic responses, they suffer from predictive biases due to species differences, and are time-consuming and costly, making them unsuitable for high-throughput toxicity screening. In recent years, the rise of organ-on-a-chip technology has provided a new means to simulate the microenvironment of human organs in vitro. This technology precisely controls the flow of culture medium through microscale fluid networks and combines multi-cell co-culture to reconstruct key structural features and physiological functions of organs in vitro. However, current organ-on-a-chip research still mainly focuses on single-organ models or constructs limited multi-organ systems around a single exposure pathway, such as the gut-liver axis or lung-heart axis models. These systems cannot simultaneously reproduce the continuous cross-barrier transport and systemic circulation of microplastics after ingestion via the digestive tract and inhalation via the respiratory tract, and are insufficient to accurately reflect the distribution characteristics of microplastics in distal organs in vivo and their cumulative cardiac toxicity. Furthermore, different studies lack unified standards in terms of organ combinations, cell sources, and culture conditions, and experimental results are highly dependent on specific model configurations, limiting the comparability and systematic nature of health risk assessments. Summary of the Invention

[0005] To overcome the shortcomings of the prior art, this invention provides a dual-channel intestinal-liver-heart-lung organ-on-a-chip system and its preparation method, aiming to solve the problem that existing chips cannot simultaneously simulate the transorganizational transport of microplastics through both respiratory and digestive pathways and compare differences in cardiotoxicity, thus providing a more realistic in vitro model for environmental health risk assessment.

[0006] To achieve the above objectives, one or more embodiments of the present invention provide the following technical solutions: The first aspect of this invention provides a dual-channel intestinal-liver-heart-lung organ-on-a-chip system; A dual-channel intestinal-liver-heart-lung organ-on-a-chip system includes a chip body, wherein the chip body consists of a microvalve layer, a flexible thin film layer and a microchannel layer from bottom to top, and the three layers are bonded by plasma treatment. The microchannel layer integrates multiple cell culture chambers and circulatory pathways, and the cross-section of the microchannels is an arc-shaped structure; the circulatory pathways include a first circulatory pathway and a second circulatory pathway; The flexible thin film layer is disposed between the microchannel layer and the microvalve layer to isolate the fluid channel from the pneumatic control layer and to serve as a deformable structure during the microvalve actuation process. The microvalve layer contains multiple independent pneumatic microvalve chambers. By adjusting the air pressure inside the chambers, the deformation of the flexible film is changed, and the reversible opening and closing of the microchannels is controlled, thereby realizing the dynamic switching between multiple culture modes.

[0007] As a further technical solution, the cell culture chamber includes an intestinal epithelial cell culture chamber, a lung epithelial cell culture chamber, a liver cell culture chamber, and a cardiomyocyte culture chamber.

[0008] As a further technical solution, the first circulatory pathway is a respiratory exposure circulatory pathway, used to connect the lung cell culture chamber and the cardiomyocyte culture chamber; the second circulatory pathway is a digestive exposure circulatory pathway, used to connect the intestinal cell culture chamber, the liver cell culture chamber and the cardiomyocyte culture chamber.

[0009] As a further technical solution, the flexible thin film layer is a PDMS thin film layer.

[0010] As a further technical solution, dynamic switching between multiple culture modes can be achieved by controlling the reversible opening and closing of microchannels, including: It enables dynamic switching between multiple culture modes, including independent culture mode, digestion exposure cycle mode, and respiration exposure cycle mode; In the independent culture mode, each cell culture chamber is completely isolated, and each organ module undergoes independent dynamic perfusion culture; in the digestive exposure circulation mode, the intestinal cell culture chamber, the liver cell culture chamber, and the cardiomyocyte culture chamber are sequentially connected to form an intestinal-liver-heart serial pathway; in the respiratory exposure circulation mode, the lung cell culture chamber and the cardiomyocyte culture chamber are directly connected to form a lung-heart direct circulation pathway.

[0011] The second aspect of the present invention provides a method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system.

[0012] A method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system, comprising: S1, Polydimethylsiloxane and curing agent are mixed in a predetermined ratio and then degassed under vacuum before use; S2, the obtained mixture is poured into the microchannel layer mold and the microvalve layer mold respectively, and after heating and curing, the microchannel layer PDMS structure and the microvalve layer PDMS structure are obtained respectively. After peeling, the holes are punched at the preset positions. S3, Polydimethylsiloxane and curing agent are mixed in a predetermined ratio, spin-coated onto the surface of a microchannel layer mold, and cured by heating to form a flexible film; S4. After plasma treatment, the microvalve layer PDMS structure is bonded to the unpeeled microchannel layer and flexible film to form a pre-assembled microvalve layer-flexible film-microchannel layer. S5. Peel the pre-assembled body off the microchannel layer mold, and after plasma treatment, align and bond the microchannel layer PDMS structure with one side of the microchannel layer of the pre-assembled body to complete the three-layer structure assembly. S6. The assembled chip is heated and then cured to obtain the prepared organ-on-a-chip.

[0013] As a further technical solution, in step S1, polydimethylsiloxane and curing agent are mixed at a weight ratio of 10:1 and then placed in a vacuum environment to degas until the bubbles are completely removed.

[0014] As a further technical solution, in step S2, the obtained mixture is poured into the microchannel layer mold and the microvalve layer mold respectively, and heated and cured at 65-75℃ for 3-5 h to obtain the microchannel layer PDMS structure and the microvalve layer PDMS structure respectively. After peeling, the structure is punched at the preset position.

[0015] As a further technical solution, in step S3, polydimethylsiloxane and curing agent are mixed at a weight ratio of 15-25:1, and then spin-coated onto the surface of the microchannel layer mold using a multi-segment variable speed spin coating process. After being heated and cured at 75-85℃ for 15-25 minutes, a flexible film with a thickness of 35-50μm is formed.

[0016] As a further technical solution, in step S6, the assembled chip is placed in an oven at 75-85℃ and heated for 15-25 minutes to cure it, thereby obtaining the prepared organ chip.

[0017] The above one or more technical solutions have the following beneficial effects: (1) This invention integrates a pneumatic microvalve system to achieve dynamic switching between three culture modes on a single chip: independent culture mode, digestive exposure cycle mode, and respiratory exposure cycle mode. This can simultaneously simulate the cross-barrier transport and multi-organ interaction processes of microplastics after they enter the human body via the respiratory pathway (lung-heart direct circulation) and the digestive pathway (intestinal-liver-heart serial circulation). This design overcomes the shortcomings of traditional single-organ models or single exposure pathway models that cannot truly reflect the systemic toxicity of microplastics. It enables direct comparison of cardiotoxicity caused by different exposure pathways under unified experimental conditions, providing an in vitro research platform that is closer to the real in vivo state for the health risk assessment of environmental pollutants.

[0018] (2) This invention employs a three-layer bonding structure consisting of a microchannel layer, a PDMS flexible film layer, and a microvalve layer. By adjusting the air pressure within the pneumatic microvalve chamber, the PDMS film is deformed, enabling reversible opening and closing of the microchannel. After optimization, when the driving pressure reaches 60 kPa, the maximum displacement of the PDMS film reaches 0.542 mm, which can completely seal the semi-circular microchannel. Under a continuous perfusion flow rate of 200 μL / h, the microvalve can maintain a stable closed state without liquid leakage, ensuring the stability and reliability of the chip under multi-mode switching and long-term operation conditions, and providing a solid technical foundation for dynamic co-culture of multiple organs.

[0019] (3) This invention precisely controls the perfusion flow rate of each culture chamber (200 μL / h for intestinal, lung, and hepatocytes, and 100 μL / h for cardiomyocytes) to keep the wall shear stress below 0.01 dyn / cm², which is within the tolerable range for each cell type. Experiments show that, compared with static culture, under dynamic conditions, the expression of ZO-1 in intestinal epithelial cells increased by 29.60%, the urea secretion of hepatocytes was 2.83 times that of the static group, the expression of CX43 in cardiomyocytes was about twice that of the static group, and the expression of sarcomere structures increased by 8.91%. This system can maintain the structural integrity and functional stability of multi-organ cells in a dynamic microenvironment for a long time, which is significantly better than the traditional static culture model.

[0020] Advantages of additional aspects of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. Attached Figure Description

[0021] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an improper limitation of the invention.

[0022] Figure 1 This is a flowchart of the method in the first embodiment.

[0023] Figure 2 This is a schematic diagram illustrating the performance verification of the microvalve and the switching between multiple culture modes in the first embodiment.

[0024] Figure 3 This is a schematic diagram comparing the multi-organ toxicity effects of microplastics after inhalation and digestion in the first embodiment.

[0025] Figure 4 This is a system structure diagram of the second embodiment. Detailed Implementation

[0026] It should be noted that the following detailed descriptions are exemplary and intended to provide further illustration of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0027] It should be noted that the terminology used herein is for the purpose of describing particular implementations only and is not intended to limit the exemplary implementations of the present invention.

[0028] Where there is no conflict, the embodiments and features in the embodiments of the present invention can be combined with each other.

[0029] Example 1 This embodiment discloses a dual-channel intestinal-liver-heart-lung organ-on-a-chip system; like Figure 1 As shown, a dual-channel gut-liver-heart-lung organ-on-a-chip (DPOC) system includes a chip body with a three-layer structure, consisting of a microvalve layer, a flexible thin film layer, and a microchannel layer from bottom to top. The three layers are bonded together by plasma treatment. The chip body measures 5 cm × 5 cm × 0.6 cm.

[0030] The microchannel layer integrates multiple cell culture chambers and circulation pathways. Specifically, the microchannel layer includes 8 microchannel interfaces, 4 cell culture chambers, and 10 microvalve control interfaces. The microchannel cross-section is arc-shaped, preferably semi-circular, with a diameter of 1 mm to reduce fluid resistance and improve the stability of culture medium transport. The 4 cell culture chambers are used to accommodate intestinal epithelial cell models (Caco-2 cells), lung epithelial cell models (A549 cells), hepatocyte models (HepaRG cells), and cardiomyocyte models (primary cardiomyocytes), respectively.

[0031] The circulatory pathways include a first circulatory pathway and a second circulatory pathway that are independent of each other but can operate in parallel. The first circulatory pathway is a respiratory exposure circulatory pathway, which connects the lung cell culture chamber and the cardiomyocyte culture chamber, simulating the process by which microplastics are transported across the alveolar barrier and directly enter the systemic circulation and are delivered to the heart. The second circulatory pathway is a digestive exposure circulatory pathway, which connects the intestinal cell culture chamber, the hepatocyte culture chamber, and the cardiomyocyte culture chamber, simulating the dynamic transport path of microplastics after absorption by the intestine, first-pass metabolism by the liver, and then entry into the heart.

[0032] The flexible thin film layer is a PDMS thin film layer with a thickness of 40 μm, disposed between the microchannel layer and the microvalve layer. It is used to isolate the fluid channel from the pneumatic control layer and serves as a deformable structure during the microvalve actuation process. The microvalve system in DPOC achieves reversible opening and closing of the channel based on the pneumatic deformation of the PDMS flexible thin film.

[0033] Specifically, when compressed air is injected into the microvalve layer's gas chamber, the pressure inside the chamber increases, causing the PDMS film to deform upwards and adhere to the bottom of the microchannel above, thereby blocking fluid flow. When the air pressure is released, the PDMS film returns to its initial state, and the microchannel reopens. Since the microvalve's closing performance is directly affected by the air pressure, determining the appropriate driving pressure is crucial for achieving stable sealing and extending chip lifespan. Too low a pressure may lead to incomplete sealing, while too high a pressure may cause PDMS structural fatigue or even chip delamination failure.

[0034] Therefore, the deformation behavior of PDMS thin films under different pressure conditions was first simulated and analyzed using the finite element method. The simulation results are as follows: Figure 2 As shown in Figures a, b, c, and d, the center displacement of the PDMS film gradually increases with increasing air pressure. When the driving pressure reaches 60 kPa, the maximum displacement of the film reaches 0.542 mm, exceeding the 0.5 mm height of the semi-circular microchannel, indicating that the PDMS film can now completely adhere to the bottom of the microchannel, thus achieving effective sealing. Figure 2 The working principle of the microvalve is further illustrated in Figure e. To verify the reliability of the finite element simulation results, a pneumatic drive experiment was conducted on the prepared DPOC. Before the experiment, a calibration relationship between the volume of compressed air in the syringe and the pressure inside the microvalve's air chamber was established. During the experiment, the total infusion volume of the syringe pump was set to 1.2 mL, the infusion rate was 2 mL / min, and the air chamber pressure data was collected in real time through a serial port debugging system. Finally, the correspondence between the compressed air volume and the air pressure was obtained, as shown in the figure. Figure 2 As shown in Figure g. The results show that when the volume of compressed air in the syringe reaches 0.8 mL, the pressure in the microvalve chamber is approximately 55.41 kPa, at which point the microvalve is closed as shown in Figure g. Figure 2 As shown in Figure f, the PDMS film maintains a tight fit with the microchannel, achieving a stable and leak-free seal. Further experiments revealed insufficient sealing performance of the microvalve under lower pressures, while higher pressures easily lead to chip structure damage and interlayer delamination. Therefore, in this embodiment, a pressure of 0.8 mL was ultimately selected as the optimal closing parameter for the microvalve. Under this optimized condition, even at a continuous infusion flow rate of 200 μL / h, the microvalve remained stably closed without liquid leakage, thus ensuring the long-term stability and reliability of the DPOC operation.

[0035] The microvalve layer comprises 10 independent pneumatic microvalve chambers, each with a diameter of 1 mm. By adjusting the air pressure within the chambers to change the deformation of the PDMS film, the reversible opening and closing of the microchannels can be controlled, thereby enabling dynamic switching between various culture modes.

[0036] Specifically, by adjusting the opening and closing states of microvalves at different locations, the following three cultivation modes can be dynamically switched: (1) Independent culture mode: Apply air pressure to the micro-valve at a specific location to close the corresponding channel, completely isolate each cell culture chamber, and conduct independent dynamic perfusion culture of each organ module to promote cell maturation and the establishment of organ-specific functions.

[0037] (2) Digestion exposure cycle mode: Adjust the opening and closing state of the micro valve to connect the intestinal cell culture chamber, the liver cell culture chamber and the cardiomyocyte culture chamber in sequence to form an intestinal-liver-heart serial pathway, which is used to simulate the cross-organ transport process of microplastics after exposure through the digestive pathway.

[0038] (3) Respiratory exposure circulation mode: Adjust the opening and closing state of the microvalve to directly connect the lung cell culture chamber and the cardiomyocyte culture chamber to form a direct lung-heart circulation pathway, which is used to simulate the cross-barrier transport process of microplastics after exposure via the respiratory route.

[0039] Based on an integrated pneumatic microvalve system, DPOC achieves the three dynamically switchable culture modes mentioned above. This system adjusts the opening and closing states of microvalves at different locations, altering the connectivity of corresponding microchannels, thereby enabling flexible switching between different circulation paths. First, in the single-organ independent culture mode, pneumatic pressure is applied to microvalves at specific locations, closing the corresponding channels and achieving complete isolation between cell culture chambers. For example... Figure 2As shown in h(i), the red dye is confined to the corresponding microchannel, indicating that there is no liquid crosstalk between the different circulation pathways. In this mode, each organ module can undergo independent dynamic perfusion culture to promote cell maturation and the establishment of organ-specific functions. After the cells have completed pre-culture, DPOC can be further switched to a digestion-exposed circulation mode by adjusting the opening status of microvalves at other locations, such as... Figure 2 As shown in h(ii) or the respiratory exposure circulatory pattern, as shown in h(ii) Figure 2 As shown in h(iii), the digestive cycle is used to establish a series pathway from the intestine to the liver to the heart, while the respiratory cycle is used to construct a direct lung-heart circulation pathway, thus simulating the in vivo transport process of microplastics after different exposure pathways. To verify the stability of the microvalve system under long-term operating conditions, dynamic perfusion tests were conducted on the three culture modes for 4 hours. No obvious leakage or inter-channel permeation was observed during the experiment, indicating that the designed pneumatic microvalve structure can maintain stable and reliable sealing performance under long-term perfusion conditions, providing an important guarantee for the continuous operation of the multi-mode circulation system. Overall, this switchable culture strategy endows DPOC with highly flexible microenvironment regulation capabilities, enabling it not only to meet the specific culture requirements of different organ modules, but also to achieve dynamic organ interconnection under complex exposure pathways. This provides an important technical foundation for subsequent research on microphysiological systems, toxicity evaluation, and applications related to personalized medicine.

[0040] Microplastics can enter the human body through various exposure routes, inducing oxidative stress, inflammatory responses, and cellular dysfunction. However, systematic research is still lacking on how microplastics cross the alveolar barrier after inhalation, enter systemic circulation, and further mediate distal organ damage. As the main entry point for microplastic exposure in the air, the respiratory system not only determines the initial deposition and absorption efficiency of particles but may also directly affect their distribution behavior in systemic circulation and their potential toxic effects on critical organs such as the heart. Based on this, a dual-circulation multi-organ on-chip platform was constructed to simulate the alveolar barrier transport process of microplastics after exposure via the respiratory route and to further evaluate its impact on the structure and function of downstream cardiomyocytes. After the cells of each organ in the DPOC were cultured to a relatively stable and mature state on day 7, the chip was switched to respiratory circulation mode to establish a dynamic lung-heart circulation pathway, such as... Figure 3 As shown in Figure a.

[0041] In the lung organ module, immunofluorescence results of the tight junction protein ZO-1 in A549 cells showed significant concentration-dependent structural changes. In the control group, ZO-1 exhibited a continuous and intact ring distribution along the cell boundaries, indicating that the lung epithelial barrier structure maintained good integrity. However, with increasing microplastic exposure concentration, especially at ≥50 μg / mL, the ZO-1 signal gradually showed fragmentation, internalization, and diffuse distribution, suggesting that the tight junction structure between cells was disrupted and the alveolar barrier integrity decreased. Figure 3 As shown in figures b and d. Meanwhile, the intracavitary NO release level significantly increases with increasing microplastic concentration, as shown in... Figure 3 As shown in Figure c, microplastic exposure induces a significant inflammatory stress response. Considering that NO is not only an important signaling molecule in the inflammatory process but also has a strong diffusion capacity, its elevated expression may not only reflect local lung inflammation activation but may also serve as an important mediator of cross-organ signal transduction, further participating in the functional regulation and damage processes of downstream organs.

[0042] In the cardiac module, microplastics transported via the circulatory system caused significant structural and functional damage to primary cardiomyocytes. Immunofluorescence results of α-actinin showed that control group cardiomyocytes possessed a clear and regular sarcomere striation structure, while with increasing microplastic exposure concentration, myofibril arrangement gradually became disordered, exhibiting significant breakage and diffusion at 100 μg / mL. Figure 3 As shown in Figure b. Further quantitative analysis revealed that the sarcomere length of cardiomyocytes significantly decreased from 1.79 ± 0.13 μm to 1.48 ± 0.10 μm, exhibiting a clear dose-dependent decreasing trend, as shown in Figure b. Figure 3 As shown in Figure e, since sarcomere structure is the core basis for maintaining myocardial contractile function, its impaired integrity signifies substantial damage to the myocardial contractile apparatus. Simultaneously, the expression level of the gap junction protein CX43 also decreased significantly with increasing microplastic concentration, reaching only about 25.1% of the control group in the high-concentration exposure group. Figure 3 As shown in f, the decreased expression of CX43, a key protein for maintaining synchronized electrical signal transduction between cardiomyocytes, indicates suppressed intercellular electrical coupling, which may further induce myocardial rhythm abnormalities. Notably, dysregulation of CX43 expression and disruption of sarcomere structure reveal the potential mechanisms by which microplastics induce myocardial dysfunction from both the electrical signal transduction and contractile structure perspectives, respectively. Further oxidative stress analysis showed that ROS fluorescence intensity continuously increased with increasing microplastic concentration, suggesting that microplastic exposure can induce abnormal accumulation of reactive oxygen species within cardiomyocytes, such as… Figure 3As shown in Figure g. Excessive ROS can not only directly attack cell membrane lipids, proteins, and DNA, but may also further activate inflammation and apoptosis-related signaling pathways, thereby amplifying the cell damage effect. This suggests that oxidative stress may be one of the key driving mechanisms of microplastic-mediated cardiotoxicity. At the functional level, the myocardial injury-related markers NT-proBNP and cTnT both showed significant dose-dependent increases. Among them, NT-proBNP increased from 86.86 ± 7.70 ng / L to 399.50 ± 12.02 ng / L. Figure 3 As shown in the figure, the cardiomyocytes are in a state of continuous stress and dysfunction; while cTnT increased from 21.32 ± 3.98 ng / L to 257.60 ± 18.70 ng / L. Figure 3 As shown in Figure i, this further demonstrates that the integrity of the cardiomyocyte membrane was disrupted and significant cell damage occurred. The simultaneous increase of the two markers indicates that microplastics not only affect the functional homeostasis of cardiomyocytes but also induce definite structural damage. Furthermore, the spontaneous beating frequency of cardiomyocytes also decreased significantly with increasing microplastic concentration, from 0.82 Hz in the control group to 0.35 Hz, a decrease of more than 50%. Figure 3 As shown in Figure j. This result further validates the synergistic effect between the aforementioned sarcomere damage, abnormal electrical signal transduction, and oxidative stress at the overall functional level, indicating that microplastics, after exposure via the respiratory route, can cause systemic damage to myocardial function through transorganizational transport.

[0043] In summary, microplastics exposed via the respiratory route can first disrupt the integrity of the alveolar epithelial barrier and induce a significant inflammatory response, thereby promoting the entry of inflammatory mediators and microplastics themselves into the circulatory system. Subsequently, these circulatory damaging factors further act on downstream cardiomyocytes, gradually inducing a cascade of toxicity: oxidative stress – structural damage – abnormal electrical conduction – functional decline. These results not only highlight the crucial role of the lungs as the primary interface for microplastic exposure in vivo but also reveal the potential biological pathway by which microplastics mediate systemic cardiotoxicity under respiratory exposure conditions, providing new mechanistic evidence for understanding the cardiovascular health risks associated with airborne microplastic exposure.

[0044] Compared to the respiratory pathway where microplastics cross the alveolar barrier and directly enter the systemic circulation, the digestive pathway involves multiple organ-mediated processes, including intestinal absorption, first-pass metabolism in the liver, and systemic circulatory transport. Therefore, the mechanisms of toxicity transfer and amplification may differ significantly. In particular, intestinal barrier function, hepatic metabolic capacity, and inter-organ inflammatory signal transduction can all influence the toxic effects of microplastics upon reaching the heart. Therefore, a systematic comparative analysis of the inter-organ transport behavior of microplastics and their induced myocardial injury processes under respiratory and digestive exposure pathways is necessary.

[0045] Further comparison of cardiotoxicity under different exposure routes revealed that the two routes exhibited significantly different toxicity evolution characteristics at different exposure doses, such as... Figure 3 As shown in the figures (k, l, m), under low-concentration microplastic exposure conditions, the respiratory pathway, bypassing the first-pass effect of the liver and directly entering the systemic circulation, exhibits a faster and more direct damaging effect on cardiomyocytes. However, as the microplastic concentration further increases, the toxicity associated with the digestive pathway rapidly increases and gradually surpasses the damage caused by the respiratory pathway. For example, under 100 μg / mL microplastic exposure conditions, the levels of NT-proBNP and cTnT in the digestive pathway group were significantly higher than those in the respiratory pathway, accompanied by more significant sarcomere shortening, with sarcomere length decreasing to approximately 1.23 μm. This indicates that under high-load exposure conditions, the synergistic effect of multiple organs in the digestive system can further amplify the systemic toxic effects of microplastics. Combining the aforementioned results, it can be inferred that the process of "intestinal barrier disruption—hepatic metabolic amplification—systemic inflammatory spread" in the digestive pathway may constitute a sustained chain of toxicity enhancement. Among them, damage to the intestinal epithelial barrier promotes the entry of microplastics and inflammatory factors into the circulatory system, while the liver further releases oxidative stress-related molecules and pro-inflammatory mediators during metabolic stress and inflammatory activation, which ultimately act together on downstream cardiomyocytes, thereby inducing more severe structural damage and functional decline under high concentration exposure conditions.

[0046] In summary, microplastics exposed via the digestive route can amplify inflammatory responses and metabolic stress signals through multi-organ crosstalk between the gut, liver, and heart, ultimately inducing more severe structural damage and functional decline in cardiomyocytes. Compared to direct circulatory exposure via the respiratory route, the digestive route's process of "intestinal barrier imbalance—liver stress amplification—systemic inflammatory spread" is more likely to create a sustained toxic enhancement effect, thereby exacerbating downstream myocardial damage. This study reveals key differences in the formation of microplastic cardiotoxicity through different exposure routes from a systems biology perspective, emphasizing the important role of multi-organ interactions in the assessment of environmental pollutant toxicity. Furthermore, this study provides new experimental evidence and theoretical support for understanding the mechanisms underlying cardiovascular risks associated with environmental microplastics.

[0047] Example 2 This embodiment discloses a method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system; like Figure 4 As shown, a method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system includes: S1, mix polydimethylsiloxane and curing agent in a predetermined ratio, and then degas the mixture under vacuum for later use.

[0048] Polydimethylsiloxane (PDMS) and a curing agent are mixed in a predetermined ratio and then subjected to vacuum degassing before use. Preferably, PDMS and the curing agent are mixed at a weight ratio of 10:1 and then placed in a vacuum environment for degassing until all bubbles are removed, ensuring that there are no bubble defects inside the structure during subsequent casting.

[0049] S2, the obtained mixture is poured into the microchannel layer mold and the microvalve layer mold respectively, and after heating and curing, microchannel layer PDMS structure and microvalve layer PDMS structure are obtained respectively. After peeling, holes are punched at the preset positions.

[0050] The mixture obtained in step S1 is poured into the prefabricated microchannel layer mold and microvalve layer mold respectively. After heating and curing, microchannel layer PDMS structure and microvalve layer PDMS structure are obtained respectively. After peeling, holes are punched at the preset positions.

[0051] As a preferred embodiment, the obtained mixture is poured into a microchannel layer mold and a microvalve layer mold, respectively, and cured at 65-75℃ for 3-5 hours. The microchannel layer mold comprises a male mold structure with 8 microchannel interfaces, 4 cell culture chambers, and 10 microvalve control interfaces; the microchannels have a semi-circular cross-section with a diameter of 1 mm. The microvalve layer mold comprises a male mold structure with 10 independent pneumatic microvalve chambers, each with a diameter of 1 mm. After curing, the structure is carefully peeled off, and holes are punched at preset positions. It is then wrapped with plastic wrap for later use.

[0052] S3 involves mixing polydimethylsiloxane and a curing agent in a predetermined ratio, spin-coating the mixture onto the surface of a microchannel layer mold, and then heating and curing it to form a flexible film.

[0053] Polydimethylsiloxane and a curing agent are mixed in a predetermined ratio, spin-coated onto the surface of a microchannel layer mold, and cured by heating to form a flexible film.

[0054] As a preferred embodiment, PDMS and a curing agent are mixed at a weight ratio of 15-25:1 and then spin-coated onto the surface of a microchannel layer mold using a multi-stage variable-speed spin coating process. The multi-stage variable-speed spin coating process includes a first stage spin coating and a second stage spin coating, wherein the spin speed of the first stage spin coating is lower than that of the second stage spin coating. Specifically, the spin coating parameters for the first stage are 400-600 rpm × 8-12 s, and the spin coating parameters for the second stage are 1200-1800 rpm × 8-12 s; more preferably, 500 rpm × 10 s, followed by 1500 rpm × 10 s, to form a flexible film with a thickness of 35-50 μm (preferably 40 μm). After spin coating, the film is heated and cured at 75-85℃ for 15-25 min (preferably 80℃ for 20 min) to form a PDMS flexible film layer. This flexible film layer is used to subsequently isolate the fluid channels from the pneumatic control layer and serves as a deformable structure during the microvalve actuation process.

[0055] S4. After plasma treatment, the microvalve layer PDMS structure is bonded to the unpeeled microchannel layer and flexible film to form a pre-assembled microvalve layer-flexible film-microchannel layer.

[0056] After plasma treatment of the microvalve layer PDMS structure obtained in step S2, it is bonded to the microchannel layer and flexible film that were not peeled off in step S3 to form a pre-assembled microvalve layer-flexible film-microchannel layer.

[0057] As a preferred embodiment, the microvalve layer PDMS structure is subjected to oxygen plasma treatment for 40-80 s (preferably 60 s) and then immediately bonded to the unpeeled microchannel layer and flexible film to form a pre-assembled structure. Oxygen plasma treatment activates the PDMS surface, enabling it to form irreversible chemical bonds with another PDMS layer, ensuring strong interlayer bonding.

[0058] S5. Peel the pre-assembled body from the microchannel layer mold, and after plasma treatment, align and bond the microchannel layer PDMS structure with one side of the microchannel layer of the pre-assembled body to complete the three-layer structure assembly.

[0059] Peel the pre-assembled body obtained in step S4 from the microchannel layer mold, and after plasma treatment, align and bond the microchannel layer PDMS structure obtained in step S2 with one side of the microchannel layer of the pre-assembled body to complete the three-layer structure assembly.

[0060] As a preferred option, the microchannel layer PDMS structure is treated with oxygen plasma for 40-80 s (preferably 60 s), and then precisely positioned by alignment marks on the mold, and aligned and bonded to one side of the microchannel layer of the pre-assembled body to complete the three-layer structure assembly.

[0061] S6. The assembled chip is heated and then cured to obtain the prepared organ-on-a-chip.

[0062] The assembled chip in step S5 is then heated and cured to obtain the prepared organ-on-a-chip.

[0063] As a preferred method, the assembled chip is placed in an oven at 75-85℃ (preferably 80℃) for post-curing treatment for 15-25 min (preferably 20 min) to further enhance the interlayer bonding strength between the three-layer structure of the microchannel layer, flexible film layer, and microvalve layer. After post-curing, the chip is allowed to cool naturally to room temperature for later use.

[0064] In steps S1-S6 above, the oxygen plasma treatment conditions in steps S4 and S5 are the same, both involving oxygen plasma treatment for 60 seconds. The bonding operation is performed within 30 seconds after the oxygen plasma treatment to avoid surface activity failure.

[0065] Before use, the chip needs to be disinfected and sterilized: inject 75% ethanol into the chip to disinfect the microchannels and cell culture chamber for 30 minutes, then dry it in a 60°C oven and sterilize it by UV / ozone treatment for 30 minutes before it can be used for cell culture experiments.

[0066] While the specific embodiments of the present invention have been described above in conjunction with the accompanying drawings, this is not intended to limit the scope of protection of the present invention. Those skilled in the art should understand that various modifications or variations that can be made by those skilled in the art without creative effort based on the technical solutions of the present invention are still within the scope of protection of the present invention.

Claims

1. A dual-channel intestinal-liver-heart-lung organ-on-a-chip system, characterized in that, The chip body consists of a microvalve layer, a flexible thin film layer, and a microchannel layer from bottom to top. The three layers are bonded together by plasma treatment. The microchannel layer integrates multiple cell culture chambers and circulatory pathways, and the cross-section of the microchannels is an arc-shaped structure; the circulatory pathways include a first circulatory pathway and a second circulatory pathway; The flexible thin film layer is disposed between the microchannel layer and the microvalve layer to isolate the fluid channel from the pneumatic control layer and to serve as a deformable structure during the microvalve actuation process. The microvalve layer contains multiple independent pneumatic microvalve chambers. By adjusting the air pressure inside the chambers, the deformation of the flexible film is changed, and the reversible opening and closing of the microchannels is controlled, thereby realizing the dynamic switching between multiple culture modes.

2. The dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 1, characterized in that, The cell culture chambers include intestinal epithelial cell culture chambers, lung epithelial cell culture chambers, liver cell culture chambers, and cardiomyocyte culture chambers.

3. The dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 1, characterized in that, The first circulatory pathway is a respiratory exposure circulatory pathway, used to connect the lung cell culture chamber and the cardiomyocyte culture chamber; the second circulatory pathway is a digestive exposure circulatory pathway, used to connect the intestinal cell culture chamber, the hepatocyte culture chamber and the cardiomyocyte culture chamber.

4. The dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 1, characterized in that, The flexible thin film layer is a PDMS thin film layer.

5. A dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 1, characterized in that, By controlling the reversible opening and closing of microchannels, dynamic switching between multiple culture modes can be achieved, including: It enables dynamic switching between multiple culture modes, including independent culture mode, digestion exposure cycle mode, and respiration exposure cycle mode; In the independent culture mode, each cell culture chamber is completely isolated, and each organ module undergoes independent dynamic perfusion culture; in the digestive exposure circulation mode, the intestinal cell culture chamber, the liver cell culture chamber, and the cardiomyocyte culture chamber are sequentially connected to form an intestinal-liver-heart serial pathway; in the respiratory exposure circulation mode, the lung cell culture chamber and the cardiomyocyte culture chamber are directly connected to form a lung-heart direct circulation pathway.

6. A method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system, characterized in that, include: S1, Polydimethylsiloxane and curing agent are mixed in a predetermined ratio and then degassed under vacuum before use; S2, the obtained mixture is poured into the microchannel layer mold and the microvalve layer mold respectively, and after heating and curing, the microchannel layer PDMS structure and the microvalve layer PDMS structure are obtained respectively. After peeling, the holes are punched at the preset positions. S3, Polydimethylsiloxane and curing agent are mixed in a predetermined ratio, spin-coated onto the surface of a microchannel layer mold, and cured by heating to form a flexible film; S4. After plasma treatment, the microvalve layer PDMS structure is bonded to the unpeeled microchannel layer and flexible film to form a pre-assembled microvalve layer-flexible film-microchannel layer. S5. Peel the pre-assembled body off the microchannel layer mold, and after plasma treatment, align and bond the microchannel layer PDMS structure with one side of the microchannel layer of the pre-assembled body to complete the three-layer structure assembly. S6. The assembled chip is heated and then cured to obtain the prepared organ-on-a-chip.

7. The method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 6, characterized in that, In step S1, polydimethylsiloxane and curing agent are mixed at a weight ratio of 10:1 and then placed in a vacuum environment to degas until the bubbles are completely removed.

8. The method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 6, characterized in that, In step S2, the obtained mixture is poured into the microchannel layer mold and the microvalve layer mold respectively, and heated and cured at 65-75℃ for 3-5 h to obtain the microchannel layer PDMS structure and the microvalve layer PDMS structure respectively. After peeling, the structure is punched at the preset position.

9. The method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 6, characterized in that, In step S3, polydimethylsiloxane and curing agent are mixed at a weight ratio of 15-25:1 and then spin-coated onto the surface of the microchannel layer mold using a multi-stage variable speed spin coating process. After being heated and cured at 75-85℃ for 15-25 min, a flexible film with a thickness of 35-50μm is formed.

10. The method for fabricating a dual-channel intestinal-liver-heart-lung organ-on-a-chip system as described in claim 6, characterized in that, In step S6, the assembled chip is placed in an oven at 75-85℃ and heated for 15-25 minutes to cure it, thus obtaining the prepared organ-on-a-chip.